CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
Colchicinedrug
Likely dose
Colchicine 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01935700
NCT01935700Phase 2Completed
CompareCT.gov

Evaluation the Potential of Colchicine for the Palliative Management of Hepatocellular Carcinoma Patients With Distant Metastasis or Large Vessel Invasion

Kaohsiung Medical University Chung-Ho Memorial Hospital·interventional·Posted Sep 5, 2013·Updated Aug 19, 2020

In Brief

A Phase 2 clinical trial evaluating Colchicine for Hepatocellular Carcinoma and 2 related conditions. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This trial is to evaluate the potential of colchicine for the palliative management of hepatocellular carcinoma patients with distant metastasis or large vessel invasion using the Department of Health R.O.C. approved doses and methods of administration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma, Metastasis, Invasion
CountriesTaiwan
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 5, 2013
Enrollment StartJun 6, 2013
Primary CompletionMay 31, 2019
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 12.8 years ago

Interventions

Colchicinedrug

Adjustment the dosage of colchicine during study: The colchicine dosage will be changed when the hepatic reserved function of the participant changes from Child A to B according as following: 2 tablets after breakfast, 1 tablet after lunch and 2 tablets after dinner; continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial. If the hepatic reserved function of the participant changes to Child C, colchicine will be stopped and participant receives regular follow-up only.If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again but the dose will be reduced 0.5 mg/day.